Status:
COMPLETED
CyberKnife for Unresectable Renal Tumors
Lead Sponsor:
Beth Israel Deaconess Medical Center
Conditions:
Renal Cancer
Eligibility:
All Genders
18-95 years
Phase:
NA
Brief Summary
This is a dose escalation study using the CyberKnife radiotherapy device for small surgical or medically untreatable renal tumors. Patients with renal tumors 5cms or less in diameter will be accrued o...
Detailed Description
The CyberKnife Robotic Radiosurgery System is a unique radiosurgical system capable of treating tumors anywhere in the body noninvasively and with sub-millimeter accuracy. The CyberKnife System delive...
Eligibility Criteria
Inclusion
- Tumor size 5 cm or less
- Radiographic evidence of malignancy or Histologically verified primary renal malignancy.
- If the kidney biopsy is inconclusive but the radiologist determines that the tumor based on the CT/MRI is highly suspicious for cancer, you may participate
- Patients with highly suspicious lesions on CT or MRI
- One -three gold fiducials placed in or around tumor
- Contradiction or patient refusal to partial or complete nephrectomy
- Age 18 or greater
- KPS score 70 or greater
Exclusion
- Irreversible coagulopathies that preclude fiducial placement
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 20 2014
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00807339
Start Date
March 1 2006
End Date
August 20 2014
Last Update
March 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215